SCHEMBL5400344

SCHEMBL5400344

[c]1ccc(-c2nc(Cn3ccnn3)cs2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.42
DRD2 P14416 2/20 0.41
DRD4 P21917 2/20 0.41
DRD3 P35462 2/20 0.41
ATP4A P20648 1/20 0.40
ATP4B P51164 1/20 0.40
GFER P55789 1/20 0.36
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
ALDH1A1 P00352 3/20 0.34
LMNA P02545 3/20 0.34
TDP1 Q9NUW8 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
TSHR P16473 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
KLKB1 P03952 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5403596 0.84 CYP19A1 (0.45) CYP19A1DRD2DRD4DRD3ATP4A
SCHEMBL5403605 0.81 KDM4E (0.56) CYP19A1ATP4AATP4BRAB9ANPC1
SCHEMBL3115301 0.76 RAB9A (0.56) CYP19A1RAB9ANPC1ALDH1A1LMNA
SCHEMBL6419690 0.76 CYP11B1 (0.43) CYP19A1DRD2DRD4DRD3ATP4A
SCHEMBL27605964 0.74 CYP19A1 (0.67) CYP19A1
SCHEMBL5389932 0.73 DRD2 (0.39) CYP19A1DRD2DRD4DRD3KLK1
SCHEMBL533107 0.71 RAB9A (0.53) DRD2DRD4DRD3GFERRAB9A
SCHEMBL2105505 0.71 GFER (0.45) DRD2DRD4DRD3GFERRAB9A
SCHEMBL446528 0.71 SMN1; SMN2 (0.57) DRD2DRD4DRD3RAB9ANPC1
SCHEMBL533222 0.71 GFER (0.41) DRD2DRD4DRD3GFERRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7259262-B2 Arylazole derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-08-21 US disclosed
US-20050124670-A1 Novel arylazole derivatives, their manufacture and use as pharmaceutical agents F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124670-A1 Novel arylazole derivatives, their manufacture and use as pharmaceutical agents CYP3A43, CYP3A5, CYP1A1 CYP19A1 96/4885DRD2 2009/4885DRD4 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.